<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833517</url>
  </required_header>
  <id_info>
    <org_study_id>RNT-Prostate</org_study_id>
    <nct_id>NCT04833517</nct_id>
  </id_info>
  <brief_title>Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)</brief_title>
  <official_title>REALITY Study: Analysis of a Prospective REgistry to Assess Outcome and Toxicity of Targeted RadionucLide TherapY in Patients With mCRPC in Clinical Routine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität des Saarlandes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective registry aims to assess outcome and toxicity of targeted radionuclide&#xD;
      therapies in patients with advanced prostate cancer in clinical routine. While the major&#xD;
      investigated treatment modality is prostate-specific membrane antigen (PSMA)-targeted&#xD;
      radioligand therapy, also other radionuclide therapies such as Ra223 and liver-directed&#xD;
      radioembolization are included. The investigators believe that prospectively assessed&#xD;
      long-term outcome data on implementation of radionuclide therapy, especially in the&#xD;
      palliative setting of advanced mCRPC, help to better define the real benefits and risks of&#xD;
      the respective treatment modalities for patients regarding survival and quality-of-life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Targeted radionuclide therapy is comprised of different modalities that may be applied in&#xD;
      advanced prostate cancer, either targeting bone metastases (mainly using Radium-223), any&#xD;
      type of metastases with PSMA-expression (Lutetium-177 and Actinium-225 labelled radioligands)&#xD;
      or loco-regionally applying internal radiation (Yttrium-90 microspheres) to metastatic liver&#xD;
      disease. While in Germany, each form of treatment is used in clinical routine, data is sparse&#xD;
      regarding the real benefits and risks of respective modalities, also when used in a&#xD;
      sequential order. As an example, patients receiving Ra223 treatment may later undergo PSMA&#xD;
      targeted radioligand therapy, with little data available on dependent response relationships&#xD;
      or cumulative risks. Prospective assessment of outcomes and toxicities in a radionuclide&#xD;
      therapy registry is apparently superior over retrospective analyses of selected patient&#xD;
      populations.&#xD;
&#xD;
      The goal of the REALITY study is to gain a better understanding of the real-life clinical&#xD;
      application of radionuclide therapies, with a focus on PSMA-targeted radioligand therapy in a&#xD;
      high-volume treatment centre, and the impact of each treatment for patient outcome.&#xD;
&#xD;
      Based on primary and secondary outcome measures the potential prediction of treatment benefit&#xD;
      by baseline patient and tumor characteristics, and early changes of biomarkers will be of&#xD;
      interest.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>PSA response</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Best PSA response and PSA response after 3 months from start of radionuclide therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PSA-PFS</measure>
    <time_frame>up to 10 years</time_frame>
    <description>PSA-based progression-free survival (PFS) according to PCWG3 criteria. From date of start of radionuclide therapy until documented and confirmed PSA-progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Overall survival. From date of start of radionuclide therapy until the date of death from any cause assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity (adverse events)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>All toxicity occurring after start of radionuclide treatment will be registered according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.03).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity-related discontinuation of radionuclide treatment</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Rate of toxicity-related discontinuation of radionuclide therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conventional imaging response</measure>
    <time_frame>up to10 years</time_frame>
    <description>Response to radionuclide therapy based on conventional imaging according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular imaging response</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Response to radionuclide therapy based on molecular imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life in patients receiving radionuclide therapy</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Quality-of-life assessed from start of radionuclide treatment by EORTC QLQ-C30 questionaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain control achieved by radionuclide therapy</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Based on VAS-BPI patient questionaires from start of radionuclide treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorbed doses achieved by radionuclide therapy</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Absorbed doses in Gy/GBq based on intra- / posttherapeutic dosimetry when available</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Castration Resistant Prostatic Cancer</condition>
  <condition>Advanced Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Lu177 PSMA RLT</arm_group_label>
    <description>Lutetium-177 prostate-specific membrane antigen (Lu177 PSMA) radioligand therapy (RLT) according to standard local protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ac225 PSMA RLT</arm_group_label>
    <description>Actinium-225 prostate-specific membrane antigen (Ac225 PSMA) radioligand therapy (RLT) according to standard local protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tandem Lu177 / Ac225 PSMA RLT</arm_group_label>
    <description>Combined Lu177 / Ac225 PSMA radioligand therapy according to standard local protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ra223 chloride</arm_group_label>
    <description>Bone-targeted Radium-223 (Ra223) radionuclide therapy in standard application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sm153 EDTMP</arm_group_label>
    <description>Bone-targeted Samarium-153 (Sm153) EDTMP radionuclide therapy in standard application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Y90 microshperes</arm_group_label>
    <description>Radioembolization with yttrium-90 (Y90) microspheres, standard methodology</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced castration-resistant prostate cancer, who receive radionuclide&#xD;
        treatment including Lutetium-177 PSMA-targeted radioligand therapy, Actinium-225&#xD;
        PSMA-targeted radioligand therapy, Radium-223 or other bone-targeted radionuclide therapy&#xD;
        and liver-directed radioembolization.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form (Registry Study Inclusion Form)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samer Ezziddin, MSc, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität des Saarlandes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samer Ezziddin, MSc, MD, PhD</last_name>
    <phone>+49 6841 16 22201</phone>
    <email>PSMA@uks.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katja Threm</last_name>
    <phone>+49 6841 16 24667</phone>
    <email>nuklearmedizin@uks.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Nuclear Medicine, Saarland University</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität des Saarlandes</investigator_affiliation>
    <investigator_full_name>Samer Ezziddin, MD</investigator_full_name>
    <investigator_title>Director, Dept. of Nuclear Medicine</investigator_title>
  </responsible_party>
  <keyword>mCRPC</keyword>
  <keyword>Radioligand Therapy</keyword>
  <keyword>PSMA</keyword>
  <keyword>PSMA-targeted Therapy</keyword>
  <keyword>Radionuclide Therapy</keyword>
  <keyword>Ra-223</keyword>
  <keyword>Bone-targeted Radionuclide Therapy</keyword>
  <keyword>Radioembolization</keyword>
  <keyword>SIRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

